Increasing access to mental health and substance use treatment, including via telehealth; Mental health & substance use disorder workforce; Federal funding for mental health and substance use programs, research and training; Preventing and reducing suicide; Medicare Part B coverage of pharmacist provided patient care services; Maintaining access to vaccines for children and adults; Medicare quality measures for and staffing of long-term care and skilled nursing facilities; Increase access to methadone for treatment of substance use; Maintain the six protected drug classes in Medicare Part D; Limiting the use of AI in health care decision making.
2026 · 3rd Quarter (July 1 - Sep 30)
AMERICAN ASSOCIATION OF PSYCHIATRIC PHARMACISTS
Filed by VENABLE LLP.
Open official filingSource-reported fields
Filing overview
- Type
- 3rd Quarter - Report
- Posted
- Oct 18, 2026
- Income
- $30,000.00
- Expenses
- Not reported
- Registrant
- VENABLE LLP
- Filing UUID
- 0298a407-e79a-4281-a7e0-db0f7635b5c3
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.